PHCentral RSS - rss http://phcentral.org FIRE feed Thu, 18 Sep 2014 11:09:26 GMT Pulmonary Hypertension Targeted Therapy Shows Promise http://www.phcentral.org/news/5351 http://www.empr.com/pulmonary-hypertension-targeted-therapy-shows-promise/article/369866/ September 19, 2014 N-acetylcysteine: no benefit in idiopathic pulmonary fibrosis http://www.phcentral.org/news/5350 http://pulmccm.org/main/2014/randomized-controlled-trials/n-acetylcysteine-benefit-whatsoever-idiopathic-pulmonary-fibrosis/?art=&utm_source=Email+Updates+from+PulmCCM&utm_campaign=1fd488e74f-USP_mar_24_2014&utm_medium=email&utm_term=0_e9d9e09c7c-1fd488e74f-312005757 September 19, 2014 PANTHER-IPF trial... in an epic demonstration. The more rigorously conducted PANTHER-IPF was stopped early in 2012 due to clear harm resulting from prednisone and azathioprine given to people with idiopathic pulmonary fibrosis.

But one appendage of PANTHER-IPF was allowed to live on: the 81 patients taking N-acetylcysteine (which seemed safe enough), and their placebo-taking controls. Those results were announced at the American Thoracic Society 2014 meeting, and published in the New England Journal in May 2014:

N-acetylcysteine showed no benefit over placebo in the treatment of idiopathic pulmonary fibrosis.
....
The same national meeting and journal issue announced the exciting success of pirfenidone and nintedanib for slowing lung function decline in IPF, and possibly even preventing IPF exacerbations and extending life for people with idiopathic pulmonary fibrosis.]]>
Protein in 'good cholesterol' may be a key to treating pulmonary hypertension http://www.phcentral.org/news/5352 http://medicalxpress.com/news/2014-08-protein-good-cholesterol-key-pulmonary.html September 18, 2014 Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called "good" cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents' heart and lung function]]> Mast Therapeutics’ AIR001 PAH Therapy All-Around Stellar in Phase 2 Clinical Trial http://www.phcentral.org/news/5349 http://pulmonaryhypertensionnews.com/2014/09/10/mast-therapeutics-air001-pah-therapy-all-around-stellar-in-phase-2-clinical-trial/ September 18, 2014 Researchers Discover Ranolazine May Be a Viable PAH Therapy http://www.phcentral.org/news/5347 http://pulmonaryhypertensionnews.com/2014/09/15/researchers-discover-ranolazine-may-viable-pah-therapy/ September 17, 2014 Can Pulmonary Hypertension Be Treated With a Plant? http://www.phcentral.org/news/5348 http://pulmonaryhypertensionnews.com/2014/09/12/can-pulmonary-hypertension-treated-plant/ September 16, 2014 ...
Lead author and assistant research scientist at the University of Florida, Gainesville, Vinayak Shenoy, Ph.D., said that among all the available therapies for PH, none target the root of the disease...]]>
Sarcoidosis-Associated Pulmonary Hypertension and Lung Transplantation for Sarcoidosis http://www.phcentral.org/news/5345 http://www.medscape.com/viewarticle/828792 September 15, 2014
Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to...
]]>
Pulmonary Arterial Hypertension Study Targets Abnormal Smooth Muscle Cell Growth http://www.phcentral.org/news/5346 http://pulmonaryhypertensionnews.com/2014/09/15/pulmonary-arterial-hypertension-study-targets-abnormal-smooth-muscle-cell-growth/ September 15, 2014 Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH http://www.phcentral.org/news/5344 http://www.plosone.org/article/info:doi/10.1371/journal.pone.0106440 September 14, 2014 Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis http://www.phcentral.org/news/5343 http://www.atsjournals.org/doi/abs/10.1164/rccm.201403-0442OC September 14, 2014 Combining Gilead’s Ambrisentan and Tadalafil in PAH Clinical Trial Reduced Risk of Clinical Failure http://www.phcentral.org/news/5342 http://pulmonaryhypertensionnews.com/2014/09/09/combining-gileads-ambrisentan-tadalafil-pah-clinical-trial-reduced-risk-clinical-failure/ September 13, 2014 Mast Therapeutics, Inc. (MSTX) Reports Positive Top Line Phase 2 Data on AIR001 http://www.phcentral.org/news/5341 http://www.streetinsider.com/Corporate+News/Mast+Therapeutics,+Inc.+(MSTX)+Reports+Positive+Top+Line+Phase+2+Data+on+AIR001/9812491.html September 13, 2014 Blocking one receptor could halt rheumatoid arthritis http://www.phcentral.org/news/5340 http://medicalxpress.com/news/2014-09-blocking-receptor-halt-rheumatoid-arthritis.html#ajTabs September 12, 2014 Use of nebivolol in patients with idiopathic pulmonary hypertension: results of the pilot study http://www.phcentral.org/news/5339 http://www.ncbi.nlm.nih.gov/pubmed/23479989 September 12, 2014
The researchers concluded: "Therapy with nebivolol in a dose of 5 mg/day for 24 weeks led to a significant functional improvement in the patients with IPH and reductions in RV dimensions and blood ET-1 levels. The therapy did not cause adverse reactions."]]>
Nebivolol and pulmonary hypertension http://www.phcentral.org/news/5338 https://www.ersnetsecure.org/public/prg_congres.abstract?ww_i_presentation=68184 September 12, 2014 Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. http://www.phcentral.org/news/5337 http://www.hindawi.com/journals/nrp/2014/704094/ September 12, 2014 [..]
Conclusions. In the future, healthcare organizations must struggle to achieve a holistic healthcare by making it more person-centred, and they must also promote cooperation between PAH centres and local healthcare providers. It is essential to determine the most appropriate and valuable path of information and communication and, thereby, the most cost-effective management of PAH or CTEPH.]]>
Using plants to produce enzyme may provide treatment for high blood pressure in lungs http://www.phcentral.org/news/5336 http://medicalxpress.com/news/2014-09-enzyme-treatment-high-blood-pressure.html September 11, 2014 Safe Dosage Established For Experimental Pulmonary Arterial Hypertension Therapy http://www.phcentral.org/news/5335 http://lungdiseasenews.com/2014/09/10/safe-dosage-established-experimental-pulmonary-arterial-hypertension-therapy/ September 11, 2014 Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. http://www.phcentral.org/news/5334 http://jama.jamanetwork.com/article.aspx?articleid=1902235 September 10, 2014 Study sheds light on how stem cells can be used to treat lung disease http://www.phcentral.org/news/5333 http://www.eurekalert.org/pub_releases/2014-09/elf-ssl090314.php September 10, 2014 United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem’s PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension http://www.phcentral.org/news/5331 http://www.pluristem.com/index.php/press-room/111-press-releases/press-room-2014/490-08-september-2014 September 9, 2014
The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5 million PLXcells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1 million cells per kilogram, while the third cohort is planned to be administered 2 million cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram...

]]>
New Targets for Treating Pulmonary Hypertension Found http://www.phcentral.org/news/5330 http://www.newswise.com/articles/new-targets-for-treating-pulmonary-hypertension-found September 9, 2014 Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies http://www.phcentral.org/news/5332 http://press.healthcare.bayer.com/en/press/news-details-page.php/15618/2014-0359 September 9, 2014 Racial Difference in Sarcoidosis Mortality in the United States. http://www.phcentral.org/news/5329 http://journal.publications.chestnet.org/article.aspx?articleid=1901902 September 8, 2014 Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension http://www.phcentral.org/news/5328 http://www.heartandlung.org/article/S0147-9563(14)00303-3/abstract September 7, 2014 New Omentin Study Sheds Light On PAH http://www.phcentral.org/news/5327 http://pulmonaryhypertensionnews.com/2014/09/02/new-omentin-study-sheds-light-on-pah/ September 7, 2014 Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension http://www.phcentral.org/news/5326 http://atvb.ahajournals.org/content/early/2014/08/28/ATVBAHA.114.304404.abstract September 6, 2014 Bosentan Makes No Impact on PH Associated With Fibrotic IIP http://www.phcentral.org/news/5325 http://www.practicalreviews.com/main/articles/b8589c50-a4e4-4f73-b46f-24f0a4488c5a.aspx September 6, 2014 Potential Therapy Targets for Pulmonary Hypertension ID’d http://www.phcentral.org/news/5324 http://www.doctorslounge.com/index.php/news/pb/49375 September 5, 2014 Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension http://www.phcentral.org/news/5323 http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=868494 September 5, 2014 ]]> Insmed To Present Novel Inhalation PAH Treatment at European Respiratory Society’s International Congress http://www.phcentral.org/news/5322 http://pulmonaryhypertensionnews.com/2014/09/04/insmed-present-novel-inhalation-pah-treatment-european-respiratory-societys-international-congress/ September 5, 2014 United Therapeutics Blocks Generic PAH Drug For Remodulin in Patent Case http://www.phcentral.org/news/5321 http://pulmonaryhypertensionnews.com/2014/09/03/united-therapeutics-blocks-generic-pah-drug-remodulin-patent-case/ September 5, 2014 Key Data from Newly-Tested PAH Drug to be Presented at European Conference http://www.phcentral.org/news/5320 http://pulmonaryhypertensionnews.com/2014/09/01/key-data-from-newly-tested-pah-drug-to-be-presented-at-european-conference/ September 4, 2014 Key protein lowering bad lipids may treat pulmonary hypertension http://www.phcentral.org/news/5319 http://www.thehealthsite.com/news/key-protein-lowering-bad-lipids-may-treat-pulmonary-hypertension/ September 3, 2014 First recommendations on all new oral anticoagulants in pulmonary embolism published http://www.phcentral.org/news/5318 http://medicalxpress.com/news/2014-08-oral-anticoagulants-pulmonary-embolism-published.html September 2, 2014 USB Pulse Oximeter Device For COPD Receives FDA Clearance In The U.S. http://www.phcentral.org/news/5317 http://lungdiseasenews.com/2014/08/29/nonin-medical-receives-fda-clearance-nonin-model-3231-usb-pulse-oximeter-u-s/ September 1, 2014 What's Going to Be Hot at ERS 2014 http://www.phcentral.org/news/5316 http://www.medscape.com/viewarticle/830646 August 31, 2014 Pulmonary Hypertension Associated With Chronic Obstructive Lung Disease and Idiopathic Pulmonary Fibrosis http://www.phcentral.org/news/5315 http://www.medscape.com/viewarticle/829905 August 31, 2014 New Merger Bolsters Development of Drug For Idiopathic Pulmonary Fibrosis, a Disease Associated With PH http://www.phcentral.org/news/5314 http://pulmonaryhypertensionnews.com/2014/08/25/new-merger-bolsters-development-of-drug-for-idiopathic-pulmonary-fibrosis-a-disease-associated-with-ph/ August 31, 2014 ILH Opens Comprehensive Pulmonary Hypertension Center http://www.phcentral.org/news/5313 http://www.healthcarejournalno.com/hjno-enews/309-enews-for-august-20-2014/1610-ilh-opens-comprehensive-pulmonary-hypertension-center August 30, 2014 Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model http://www.phcentral.org/news/5312 http://ajpheart.physiology.org/content/early/2014/08/18/ajpheart.00246.2014 August 30, 2014 Protein in 'good cholesterol' may be a key to treating pulmonary hypertension http://www.phcentral.org/news/5311 http://medicalxpress.com/news/2014-08-protein-good-cholesterol-key-pulmonary.html August 29, 2014 FDA Grants Clearance For Vibralung Acoustical Percussor Respiratory Device http://www.phcentral.org/news/5310 http://lungdiseasenews.com/2014/08/27/fda-grants-clearance-for-vibralung-acoustical-percussor-respiratory-device/ August 28, 2014 Pulmonary Hypertension & Viagra: Researchers Discover Novel Mechanisms of Sildenafil for Disease http://www.phcentral.org/news/5309 http://pulmonaryhypertensionnews.com/2014/08/26/pulmonary-hypertension-viagra-researchers-discover-novel-mechanisms-of-sildenafil-for-disease/ August 27, 2014 How accurate is the TR jet derived Pulmonary artery systolic pressure ? http://www.phcentral.org/news/5308 http://drsvenkatesan.wordpress.com/2012/02/21/how-accurate-is-the-tr-jet-derived-pulmonary-artery-systolic-pressure/ August 26, 2014
At best ,  it has only 40% correlation with cath  derived PAP...]]>
New Report Identifies Key Features in Systemic Sclerosis and PAH http://www.phcentral.org/news/5307 http://pulmonaryhypertensionnews.com/2014/08/21/new-report-identifies-key-features-in-systemic-sclerosis/ August 26, 2014 ]]> Climate Change and Dust Increase Respiratory Disease http://www.phcentral.org/news/5305 http://guardianlv.com/2014/08/climate-change-and-dust-increase-respiratory-disease/ August 25, 2014 Novel Nitric Oxide Delivery System May Someday Improve PH Treatments http://www.phcentral.org/news/5306 http://pulmonaryhypertensionnews.com/2014/08/19/novel-nitric-oxide-delivery-system-may-someday-improve-ph-treatments/ August 25, 2014 Gum Disease: a Matter of Life and Death? http://www.phcentral.org/news/5304 https://www.sys-con.com/node/3157019 August 24, 2014 Ranolacine blunts myocardial remodelling in a model of pulmonary hypertension http://www.phcentral.org/news/5303 http://cardiovascres.oxfordjournals.org/content/early/2014/08/18/cvr.cvu188.abstract August 23, 2014 A Novel Adipocytokine, Omentin, Inhibits Monocrotaline-Induced Pulmonary Arterial Hypertension In Rats http://www.phcentral.org/news/5302 http://www.sciencedirect.com/science/article/pii/S0006291X14014934 August 22, 2014 [..]
Chronic omentin treatment inhibited MCT-induced increases in PA pressure. Omentin inhibited MCT-induced right ventricular hypertrophy as well as increase of lung to body weight ratio. Histologically, omentin inhibited MCT-induced PA hyperplasia. Further, omentin inhibited the impairment of both endothelium-dependent and -independent relaxations mediated by acetylcholine and sodium nitroprusside, respectively. In conclusion, we for the first time demonstrate that chronic omentin treatment inhibits MCT-induced PAH in rats via inhibiting vascular structural remodeling and abnormal contractile reactivity.


--------------------------------------------------------------------------------]]>
Effects of Bisoprolol and Losartan Treatment in the Hypertrophic and Failing Right Heart. http://www.phcentral.org/news/5301 http://www.onlinejcf.com/article/S1071-9164(14)01128-2/abstract August 21, 2014 The researchers stated: " In our PTB-model of pressure overload induced RV hypertrophy and failure, treatment with bisoprolol and losartan did not demonstrate any beneficial effects in compensated or decompensated RV failure."]]> Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. http://www.phcentral.org/news/5300 http://onlinelibrary.wiley.com/doi/10.1111/bph.12874/abstract;jsessionid=FC357BE55C3A84537439E23637A7F026.f02t03 August 20, 2014 Novel Mechanisms of Sildenafil in Pulmonary Hypertension Involving Cytokines/Chemokines, MAP Kinases and Akt. http://www.phcentral.org/news/5299 http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0104890&representation=PDF August 20, 2014